
Jean F. Voltaire
Examiner (ID: 18083, Phone: (571)272-3953 , Office: P/2466 )
| Most Active Art Unit | 2466 |
| Art Unit(s) | 2466, 2417 |
| Total Applications | 487 |
| Issued Applications | 381 |
| Pending Applications | 55 |
| Abandoned Applications | 68 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 16053037
[patent_doc_number] => 20200188373
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-06-18
[patent_title] => COMPOSITIONS AND METHODS FOR TREATING CANCER
[patent_app_type] => utility
[patent_app_number] => 16/640902
[patent_app_country] => US
[patent_app_date] => 2018-08-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 63941
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -36
[patent_words_short_claim] => 48
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16640902
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/640902 | Compositions and methods for treating cancer | Aug 21, 2018 | Issued |
Array
(
[id] => 16086797
[patent_doc_number] => 20200197385
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-06-25
[patent_title] => THERAPEUTIC AGENT FOR CANCER CONTAINING AXL INHIBITOR AS ACTIVE INGREDIENT
[patent_app_type] => utility
[patent_app_number] => 16/641409
[patent_app_country] => US
[patent_app_date] => 2018-08-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 15725
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -23
[patent_words_short_claim] => 785
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16641409
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/641409 | THERAPEUTIC AGENT FOR CANCER CONTAINING AXL INHIBITOR AS ACTIVE INGREDIENT | Aug 21, 2018 | Abandoned |
Array
(
[id] => 13955403
[patent_doc_number] => 20190054045
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-02-21
[patent_title] => METHODS AND COMPOSITIONS FOR TREATING SKIN CONDITIONS
[patent_app_type] => utility
[patent_app_number] => 16/106582
[patent_app_country] => US
[patent_app_date] => 2018-08-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 6537
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -20
[patent_words_short_claim] => 16
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16106582
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/106582 | METHODS AND COMPOSITIONS FOR TREATING SKIN CONDITIONS | Aug 20, 2018 | Abandoned |
Array
(
[id] => 15338759
[patent_doc_number] => 10525033
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2020-01-07
[patent_title] => Use of amisulpride as an anti-emetic
[patent_app_type] => utility
[patent_app_number] => 16/105268
[patent_app_country] => US
[patent_app_date] => 2018-08-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 3550
[patent_no_of_claims] => 26
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 24
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16105268
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/105268 | Use of amisulpride as an anti-emetic | Aug 19, 2018 | Issued |
Array
(
[id] => 14306245
[patent_doc_number] => 20190142826
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-05-16
[patent_title] => IMIDAZO[1,2-A]PYRIDINE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO
[patent_app_type] => utility
[patent_app_number] => 16/101896
[patent_app_country] => US
[patent_app_date] => 2018-08-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 30378
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -9
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16101896
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/101896 | IMIDAZO[1,2-A]PYRIDINE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | Aug 12, 2018 | Abandoned |
Array
(
[id] => 13586285
[patent_doc_number] => 20180344691
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2018-12-06
[patent_title] => Substituted Phenyl Aziridine Precursor Analogs for Inhibiting Androgen-Independent Prostate Cancer Cell Growth
[patent_app_type] => utility
[patent_app_number] => 16/059771
[patent_app_country] => US
[patent_app_date] => 2018-08-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 11090
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -5
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16059771
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/059771 | Substituted phenyl aziridine precursor analogs for inhibiting androgen-independent prostate cancer cell growth | Aug 8, 2018 | Issued |
Array
(
[id] => 13586365
[patent_doc_number] => 20180344731
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2018-12-06
[patent_title] => METHOD OF TREATING BIPOLAR I AND II DISORDERS
[patent_app_type] => utility
[patent_app_number] => 16/057586
[patent_app_country] => US
[patent_app_date] => 2018-08-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 4204
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -5
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16057586
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/057586 | METHOD OF TREATING BIPOLAR I AND II DISORDERS | Aug 6, 2018 | Abandoned |
Array
(
[id] => 16807913
[patent_doc_number] => 20210130466
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-05-06
[patent_title] => Combinations of PD-1 Antagonists and Benzo[b]thiophene STING Agonists for Cancer Treatment
[patent_app_type] => utility
[patent_app_number] => 16/635059
[patent_app_country] => US
[patent_app_date] => 2018-07-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 24597
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -12
[patent_words_short_claim] => 449
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16635059
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/635059 | Combinations of PD-1 antagonists and benzo [b] thiophene STING agonists for cancer treatment | Jul 29, 2018 | Issued |
Array
(
[id] => 13867401
[patent_doc_number] => 20190030041
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-01-31
[patent_title] => Method of Inhibition of Respiratory Depression Using Positive Allosteric AMPA Receptor Modulators
[patent_app_type] => utility
[patent_app_number] => 16/046027
[patent_app_country] => US
[patent_app_date] => 2018-07-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 11142
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -8
[patent_words_short_claim] => 102
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16046027
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/046027 | Method of Inhibition of Respiratory Depression Using Positive Allosteric AMPA Receptor Modulators | Jul 25, 2018 | Abandoned |
Array
(
[id] => 13603895
[patent_doc_number] => 20180353496
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2018-12-13
[patent_title] => FORMULATIONS OF 2-(4-CHLOROPHENYL)-N-((2-(2,6-DIOXOPIPERIDIN-3-YL)-1-OXOISOINDOLIN-5-YL)METHYL)-2,2-DIFLUOROACETAMIDE
[patent_app_type] => utility
[patent_app_number] => 16/040450
[patent_app_country] => US
[patent_app_date] => 2018-07-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 35219
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -11
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16040450
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/040450 | Formulations of 2-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide | Jul 18, 2018 | Issued |
Array
(
[id] => 16009297
[patent_doc_number] => 20200179491
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-06-11
[patent_title] => COMPOSITIONS AND METHODS FOR TREATING DISEASES ASSOCIATED WITH AN IMPRINTING DEFECT
[patent_app_type] => utility
[patent_app_number] => 16/631762
[patent_app_country] => US
[patent_app_date] => 2018-07-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 18732
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -15
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16631762
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/631762 | Compositions and methods for treating diseases associated with an imprinting defect | Jul 18, 2018 | Issued |
Array
(
[id] => 13533417
[patent_doc_number] => 20180318251
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2018-11-08
[patent_title] => PHARMACEUTICAL COMPOSITION, METHODS FOR TREATING AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 16/037052
[patent_app_country] => US
[patent_app_date] => 2018-07-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 18053
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -10
[patent_words_short_claim] => 28
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16037052
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/037052 | PHARMACEUTICAL COMPOSITION, METHODS FOR TREATING AND USES THEREOF | Jul 16, 2018 | Abandoned |
Array
(
[id] => 13533523
[patent_doc_number] => 20180318304
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2018-11-08
[patent_title] => Methods of Using BTK Inhibitors to Treat Dermatoses
[patent_app_type] => utility
[patent_app_number] => 16/035276
[patent_app_country] => US
[patent_app_date] => 2018-07-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 31428
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -6
[patent_words_short_claim] => 23
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16035276
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/035276 | Methods of Using BTK Inhibitors to Treat Dermatoses | Jul 12, 2018 | Abandoned |
Array
(
[id] => 15848073
[patent_doc_number] => 10639297
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2020-05-05
[patent_title] => Ophthalmic pharmaceutical compositions and uses relating thereto
[patent_app_type] => utility
[patent_app_number] => 16/032044
[patent_app_country] => US
[patent_app_date] => 2018-07-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 2
[patent_figures_cnt] => 2
[patent_no_of_words] => 31494
[patent_no_of_claims] => 38
[patent_no_of_ind_claims] => 5
[patent_words_short_claim] => 85
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16032044
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/032044 | Ophthalmic pharmaceutical compositions and uses relating thereto | Jul 9, 2018 | Issued |
Array
(
[id] => 16358490
[patent_doc_number] => 20200315241
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-10-08
[patent_title] => Nicotine Salts and Methods of Making and Using Same
[patent_app_type] => utility
[patent_app_number] => 16/626831
[patent_app_country] => US
[patent_app_date] => 2018-06-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 20492
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -26
[patent_words_short_claim] => 11
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16626831
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/626831 | Nicotine Salts and Methods of Making and Using Same | Jun 25, 2018 | Abandoned |
Array
(
[id] => 17836359
[patent_doc_number] => 20220273664
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-09-01
[patent_title] => Mitochondrial Targeted Releasable Linker
[patent_app_type] => utility
[patent_app_number] => 16/624825
[patent_app_country] => US
[patent_app_date] => 2018-06-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 8706
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16624825
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/624825 | Mitochondrial Targeted Releasable Linker | Jun 20, 2018 | Abandoned |
Array
(
[id] => 13586245
[patent_doc_number] => 20180344671
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2018-12-06
[patent_title] => Cysteamine as Neutrophil Elastase Inhibitor
[patent_app_type] => utility
[patent_app_number] => 15/997000
[patent_app_country] => US
[patent_app_date] => 2018-06-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 6164
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -5
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15997000
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/997000 | Cysteamine as Neutrophil Elastase Inhibitor | Jun 3, 2018 | Abandoned |
Array
(
[id] => 13586393
[patent_doc_number] => 20180344745
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2018-12-06
[patent_title] => TREATMENT OF DEVELOPMENTAL DISORDERS WITH IMIDAZOLONE DERIVATIVES
[patent_app_type] => utility
[patent_app_number] => 15/995292
[patent_app_country] => US
[patent_app_date] => 2018-06-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 17152
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -31
[patent_words_short_claim] => 41
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15995292
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/995292 | TREATMENT OF DEVELOPMENTAL DISORDERS WITH IMIDAZOLONE DERIVATIVES | May 31, 2018 | Abandoned |
Array
(
[id] => 13443999
[patent_doc_number] => 20180273542
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2018-09-27
[patent_title] => Novel Alpha-Hydroxy Carboxylic Acid And Derivatives And Other Gras Based Prodrugs Of Oxycodone And Uses Thereof
[patent_app_type] => utility
[patent_app_number] => 15/992287
[patent_app_country] => US
[patent_app_date] => 2018-05-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 8176
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 58
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15992287
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/992287 | Alpha-hydroxy carboxylic acid and derivatives and other GRAS based prodrugs of oxycodone and uses thereof | May 29, 2018 | Issued |
Array
(
[id] => 16548527
[patent_doc_number] => 10881665
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2021-01-05
[patent_title] => Formulations for treatment of post-traumatic stress disorder
[patent_app_type] => utility
[patent_app_number] => 15/987933
[patent_app_country] => US
[patent_app_date] => 2018-05-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 3
[patent_figures_cnt] => 3
[patent_no_of_words] => 9950
[patent_no_of_claims] => 10
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 70
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15987933
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/987933 | Formulations for treatment of post-traumatic stress disorder | May 23, 2018 | Issued |